Insulet Corporation (PODD)
Insulet Corporation is a healthcare equipment and supplies company focused on insulin delivery systems for people with insulin-dependent diabetes in the United States and other markets. Its Omnipod platform includes the Omnipod 5 automated insulin delivery system, which uses a proprietary algorithm embedded in the pod and works with a third-party continuous glucose monitor via wireless Bluetooth communication. The company also markets Omnipod DASH, a pod-based insulin management system controlled through a smartphone-like personal diabetes manager with a color touchscreen, as well as the earlier Omnipod Insulin Management System.
In addition to its diabetes products, Insulet supplies pods for Amgen’s Neulasta Onpro kit, a delivery system used to help lower infection risk after intensive chemotherapy. The company sells primarily through the pharmacy channel and through independent distributors. Insulet was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PODD
|
$189.68
|
34.9% Upside
|
Undervalued
|
$171.91
|
22.3% Upside
|
Undervalued
|
Great
|
0.0%
|
October 29, 2026
|
26.2x
|
6.9x
|
3.2x
|
9.751 B
|
10.231 B
|
8.8%
|
99.6%
|
5.6
|
78.3%
|
